Overview
The gut-prostate axis describes the bidirectional communication between the gut microbiome and the prostate gland. Gut-derived microbial metabolites, inflammatory mediators, and immune signals influence prostatic health, while prostatic disease states alter systemic inflammation and, reciprocally, gut microbial composition.
Systematic review evidence supports gut microbiome involvement in benign prostatic hyperplasia (BPH), with specific taxonomic shifts — including enrichment of pro-inflammatory Proteobacteria and depletion of SCFA-producing Firmicutes — consistently observed across BPH cohorts (xu 2026 gut prostate axis bph systematic review). The mechanistic pathways implicated include microbial translocation through a compromised gut barrier, systemic endotoxemia, and androgen metabolism by gut bacteria.
Therapeutic Implications
Probiotic interventions targeting the gut-prostate axis have shown clinical benefit in chronic bacterial prostatitis, with randomized controlled trial evidence demonstrating reduced symptom scores and inflammatory markers (vocca 2025 probiotics chronic bacterial prostatitis rct). Broader reviews position the gut microbiome as both a preventive and therapeutic target across the spectrum of prostatic diseases, from prostatitis through BPH to prostate cancer (cao 2024 gut microbiome preventive therapeutic prostatic disease).
Cross-References
- gut testis axis — parallel gut-reproductive communication in males
- semen microbiome — reproductive tract microbial communities
- prostatitis — chronic bacterial prostatitis and gut dysbiosis
- short chain fatty acids — SCFA depletion in prostatic disease